Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Amid shifts in attitudes around family planning and contraception—and as the advent telehealth outfits like Hims & Hers and Ro define a new era of consumer-driven healthcare—the lack of a medic | Recognizing the gap in male birth control, Charlottesville, Virginia’s Contraline is stepping up to the plate, developing what it believes could be a first-in-class topical candidate that has now garnered enthusiasm from a host of big-name investors.
Contraline raised $92.5M Series B to advance NES/T Gel, a first-in-class topical male contraceptive, into phase 3 trials starting 2027. The round signals VC appetite for consumer-driven healthcare in underserved categories, positioning potential telehealth distribution.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise

Contraline could become the first to commercialise a reversible male contraceptive drug, provided the treatment is successful in…

Contraline closes $92.5M Series B to fund male contraception; Novartis begins Phase 3 actinium therapies; Tavo gets $17M Series A.

This week on "The Top Line," we’re covering some of the biggest stories across biopharma before turning to one of the industry’s…

While dealmaking and investment dollars may be flowing across biopharma once again, acute challenges tied to policy, pricing and…

Consumer health giant Haleon has tapped Microsoft to incorporate AI across its operations, joining a growing wave of healthcare…

Things are happening fast at BridgeBio as it plugs away at the launch of blockbuster-in-waiting Attruby and prepares to…